Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Cellectis S.A. is a clinical-stage biotechnology company focused on developing allogeneic (off-the-shelf) cell and gene therapies, primarily for oncology indications. The company operates within the biotechnology and cell therapy industries, with a specialization in gene-edited CAR T-cell therapies designed to treat hematologic malignancies. Its core value proposition centers on using proprietary gene-editing technologies to enable scalable, standardized cell therapy products that do not require patient-specific manufacturing.
Founded in 1999, Cellectis originally focused on genome engineering technologies and gradually transitioned toward therapeutic applications in the 2010s. The company is recognized for its early and continued development of allogeneic CAR T-cell platforms, positioning itself as a pioneer in this segment relative to autologous CAR T approaches. Cellectis is publicly listed in the United States and France and has historically combined internal R&D with strategic partnerships to advance its pipeline.
Business Operations
Cellectis generates value primarily through research and development of allogeneic CAR T-cell product candidates and through collaboration and licensing agreements. Its operations are organized around its therapeutic development activities, with the primary business segment being Allogeneic CAR T-Cell Therapy Development. The company does not currently generate material commercial product revenue and remains dependent on funding, partnerships, and equity markets to support operations.
The company controls proprietary gene-editing technologies, including TALEN-based gene editing, which it uses to modify donor T cells for therapeutic use. Cellectis conducts operations in both the United States and Europe, with clinical development activities, manufacturing capabilities, and research infrastructure supporting its pipeline. Key subsidiaries include Cellectis, Inc. in the United States, which supports clinical development, regulatory engagement, and manufacturing-related activities.
Strategic Position & Investments
Cellectis’ strategic direction emphasizes advancing its wholly owned CAR T-cell pipeline while selectively monetizing its technology platform through partnerships. The company has historically entered into collaborations with large pharmaceutical and biotechnology companies to co-develop or license gene-edited cell therapy assets, supporting both capital inflows and external validation of its technology.
Strategic investments have included internal manufacturing capabilities and continued refinement of its gene-editing platform to improve safety, efficacy, and scalability. Cellectis has also maintained ownership stakes and involvement in related biotechnology entities, including Calypso Biotech, reflecting an interest in broader immunology and inflammatory disease applications beyond oncology. Its long-term strategy remains focused on positioning allogeneic CAR T therapies as a competitive alternative to autologous treatments.
Geographic Footprint
Cellectis operates primarily across Europe and North America, with corporate headquarters in France and significant operational presence in the United States. Research, clinical development, and corporate functions are distributed between these regions to support regulatory, scientific, and commercial objectives.
The company’s international footprint enables engagement with global clinical trial sites, regulatory authorities, and strategic partners. While Cellectis does not currently have commercial operations in other continents, its clinical programs and partnerships provide indirect exposure to broader global markets.
Leadership & Governance
Cellectis is led by an executive team with experience in biotechnology, pharmaceuticals, and advanced therapeutics, emphasizing scientific rigor, disciplined capital allocation, and long-term platform development. Leadership strategy has consistently focused on advancing proprietary assets while leveraging partnerships to manage risk and funding requirements.
Key executives include:
- André Choulika – Chief Executive Officer
- Sophie Galvani – Chief Scientific Officer
- Gilles Salles – Chief Medical Officer
- Lucinda Crabtree – Chief Financial Officer
- Philippe Duchateau – Executive Vice President, Research
The company operates under a board-governed structure consistent with publicly listed biotechnology companies in both U.S. and European markets, with oversight of strategy, risk management, and executive compensation.